Research Paper Volume 13, Issue 21 pp 24271—24289

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma

NLRP3 mutations association with ICI efficacy in distinct therapies. (A, B) Association of NLRP3 mutations with response rate and prognosis in patients treated with anti-CTLA-4 agents. (C, D) NLRP3 mutations versus response rate and prognosis in patients treated with anti-PD-1 agents. (E, F) NLRP3 mutations versus response rate and prognosis in patients who received combined therapy.

Figure 5. NLRP3 mutations association with ICI efficacy in distinct therapies. (A, B) Association of NLRP3 mutations with response rate and prognosis in patients treated with anti-CTLA-4 agents. (C, D) NLRP3 mutations versus response rate and prognosis in patients treated with anti-PD-1 agents. (E, F) NLRP3 mutations versus response rate and prognosis in patients who received combined therapy.